Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Which makes sense, both are treatments for the same underlying disease
& Moraru, L
Buyers seeking to confirm manufacturing origin should contact [email protected] directly
Key areas of focus include: Regulatory and Scientific Foundations: Current FDA scientific thinking on generic GLP-1 product development, Product-Specific Guidance (PSG) development, and in vivo BE studies for GLP-1 oral products Active Pharmaceutical Ingredient (API) Characterization and Manufacturing: Comprehensive approaches to demonstrating API sameness, analytical characterization strategies, impurity profiling, and sameness assessment for peptide products Recombinant Peptide Production: Best practices for controlling host cell impurities, regulatory expectations, and risk assessment strategies Oral GLP-1 Formulation Development: Formulation and delivery innovations, bioequivalence study design for highly variable products, absorption enhancement technologies, and drug product quality expectations Device User Interface and Human Factors: Comparative analyses (CA) of device user interfaces, Comparative Use Human Factors (CUHF) study design and case examples, alternative approaches, and device platform strategies Device Quality and Integration: Quality considerations for generic injectors, drug-device interface and compatibility, manufacturing quality control, and submission coordination strategies Join us for an immersive two-day experience featuring presentations from leading experts in regulatory agencies, pharmaceutical industry, and academia
JAMA, 300 (21), 2514-2526
Switching from Semaglutide, a GLP-1 receptor agonist, to Zepbound (Tirzepatide) is possible, but should be done under the supervision of your healthcare provider
